Funded Startups in N/A
Among the 7 most recent rounds shown (latest dated 2022-04-20 and earliest dated 2020-09-01), the disclosed deal size is highly uneven: Immune Regulation (…
Among the 7 most recent rounds shown (latest dated 2022-04-20 and earliest dated 2020-09-01), the disclosed deal size is highly uneven: Immune Regulation (2020-09-21) is at $52M and NovellusDx (2020-09-21) at $57M, with the top disclosed amount being NovellusDx’s $57M on 2020-09-21. Everything else clusters far below that ceiling, including PragmatIC Printing’s $17M (2020-09-08) and StockCrowd’s $5M (2020-09-01), while Midoconline’s $700K (2022-04-20) and Buyan’s $200K (2020-09-13) sit near the low end.
The table also concentrates in a narrow September 2020 window: 6 of 7 rounds are dated between 2020-09-01 and 2020-09-21. Sector-wise, biotechnology/health care dominates with 3 of 7 entries split across Immune Regulation ($52M), NovellusDx ($57M), and Buyan (undisclosed stage; $200K). Geographic representation is spread across Cambridge, Jerusalem, London, Barcelona, and Puebla, with no single city repeated in the rows shown.
Most recent rounds
7 shownRelated listings
Frequently asked
What stands out on deal size, and where does the bulk of rounds cluster?
The largest disclosed round is NovellusDx at $57M on 2020-09-21, which dwarfs the rest of the disclosed amounts. After $57M, the next-largest disclosed figures are Immune Regulation at $52M (2020-09-21) and PragmatIC Printing at $17M (2020-09-08), while Midoconline’s $700K (2022-04-20) and Buyan’s $200K (2020-09-13) are near the floor.
Do these N/A state entries cluster in time?
Yes. 6 of 7 rounds fall between 2020-09-01 (StockCrowd) and 2020-09-21 (Immune Regulation and NovellusDx), with only Midoconline’s $700K closing later on 2022-04-20.
Are biotech or health-related categories over-represented?
Biotechnology/health care shows up in 3 of the 7 entries: Immune Regulation (Biotechnology, Health Care; $52M on 2020-09-21), NovellusDx (Biotechnology, Health Care; $57M on 2020-09-21), and Buyan (Health Care; $200K on 2020-09-13).
Which entries should be prioritized if the goal is late-2020 deal monitoring?
All but one of the rows are late-2020 dates: StockCrowd ($5M, 2020-09-01), Rotamundos ($1M, 2020-09-04), PragmatIC Printing ($17M, 2020-09-08), Buyan ($200K, 2020-09-13), and the pair on 2020-09-21 (Immune Regulation $52M and NovellusDx $57M).
Are there outliers by geography or sector compared with the rest?
By deal size, Midoconline’s $700K (2022-04-20, Puebla) is a clear low-side outlier relative to the 2020-09-21 biotech rounds at $52M and $57M. By geography repetition, Cambridge appears twice in the dataset (Immune Regulation in Cambridge; PragmatIC Printing in Cambridge), but no city repeats across more than those two rows.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.